Results 171 to 180 of about 16,167 (200)
Some of the next articles are maybe not open access.
The cardioprotective effects of mineralocorticoid receptor antagonists
Pharmacology & Therapeutics, 2014Despite state-of-the-art reperfusion therapy, morbidity and mortality remain significant in patients with an acute myocardial infarction. Therefore, novel strategies to limit myocardial ischemia-reperfusion injury are urgently needed. Mineralocorticoid receptor (MR) antagonists are attractive candidates for this purpose, since several clinical trials ...
van den Berg, T.N.A. +12 more
openaire +3 more sources
Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences
Current Opinion in Pharmacology, 2016Mineralocorticoid receptor antagonists (MRAs) are best known as potassium-sparing diuretics due to their blockade of aldosterone action in renal epithelial tissues. They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues. Currently there are only two steroidal MRAs that have been approved for use;
Jun, Yang, Morag J, Young
openaire +2 more sources
Role of mineralocorticoid receptor antagonists in kidney diseases
Drug Development Research, 2020AbstractMineralocorticoid receptor (MR) antagonists, for example, spironolactone and eplerenone, are in clinical use to treat hypertension. Increasing evidence suggests that mineralocorticoid receptor activation causes the pathogenesis and progression of chronic kidney disease.
Vishal Patel +2 more
openaire +2 more sources
The renal effects of mineralocorticoid receptor antagonists
International Journal of Cardiology, 2015Beyond its well known classic effects on renal water and electrolytes metabolism, an increasing amount of experimental and clinical evidence suggests that aldosterone contributes to the pathogenesis and progression of kidney disease. The binding of aldosterone on epithelial and non-epithelial cells of the kidney induces many deleterious effects, such ...
Stefano, Bianchi +2 more
openaire +2 more sources
Finerenone: A Novel Third-Generation Mineralocorticoid Receptor Antagonist
Cardiology in Review, 2023Finerenone is a novel third-generation, selective nonsteroidal mineralocorticoid receptor antagonist (MRA) that was approved by the Food and Drug Administration in July of 2021 for its use in adults with chronic kidney disease and Type II diabetes mellitus.
Paola, Gudino Flores +3 more
openaire +2 more sources
Mineralocorticoid receptor antagonists (MRAs)
Abstract The final process in the renin–angiotensin–aldosterone system (RAAS) is the production of the mineralocorticoid aldosterone in the adrenal glands. Aldosterone has an important role in the pathophysiology of heart failure, and concentrations of aldosterone are 20-fold higher in patients with HF compared to normal individuals ...Roy S. Gardner +3 more
openaire +1 more source
Recent Advances in Mineralocorticoid Receptor Antagonists
2011Publisher Summary This chapter focuses on recent advances in mineralocorticoid receptor (MR) antagonists. MR is a member of the nuclear hormone receptor superfamily and is structurally related to the progesterone receptor, androgen receptor, estrogen receptor, and glucocorticoid receptor.
Katerina Leftheris +2 more
openaire +1 more source
Mineralocorticoid receptor antagonists and endothelial function.
Current opinion in investigational drugs (London, England : 2000), 2008Hyperaldosteronism is associated with endothelial dysfunction and impaired vascular reactivity in patients with hypertension or congestive heart failure. When present, endothelial dysfunction is an independent predictor of adverse cardiovascular events.
Bradley A, Maron, Jane A, Leopold
openaire +1 more source